Our top pick for
I-Mab is a biotechnology business based in the US. I-Mab shares (IMAB) are listed on the NASDAQ and all prices are listed in US Dollars. I-Mab employs 228 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$66.78|
|52-week range||$32.64 - $85.40|
|50-day moving average||$70.74|
|200-day moving average||$68.34|
|Wall St. target price||$94.40|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.05|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||-5.96%|
|1 month (2021-09-15)||-1.97%|
|3 months (2021-07-15)||-9.95%|
|6 months (2021-04-15)||16.87%|
|1 year (2020-10-15)||63.48%|
|2 years (2019-10-11)||N/A|
|3 years (2018-10-11)||N/A|
|5 years (2016-10-11)||N/A|
Valuing I-Mab stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of I-Mab's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
I-Mab's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $168.3 million.
The EBITDA is a measure of a I-Mab's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$1.6 billion|
|Gross profit TTM||$1.5 billion|
|Return on assets TTM||-2.86%|
|Return on equity TTM||-0.63%|
|Market capitalisation||$5.5 billion|
TTM: trailing 12 months
There are currently 2.0 million I-Mab shares held short by investors – that's known as I-Mab's "short interest". This figure is 8.6% up from 1.8 million last month.
There are a few different ways that this level of interest in shorting I-Mab shares can be evaluated.
I-Mab's "short interest ratio" (SIR) is the quantity of I-Mab shares currently shorted divided by the average quantity of I-Mab shares traded daily (recently around 591459.82142857). I-Mab's SIR currently stands at 3.36. In other words for every 100,000 I-Mab shares traded daily on the market, roughly 3360 shares are currently held short.
However I-Mab's short interest can also be evaluated against the total number of I-Mab shares, or, against the total number of tradable I-Mab shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case I-Mab's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 I-Mab shares in existence, roughly 30 shares are currently held short) or 0.0592% of the tradable shares (for every 100,000 tradable I-Mab shares, roughly 59 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against I-Mab.
Find out more about how you can short I-Mab stock.
We're not expecting I-Mab to pay a dividend over the next 12 months.
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; and PT Kalbe Genexine Biologics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China. .
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.